Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator Drugs are widely used in Central & Western Europe to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and bronchitis. The market for these drugs has been steadily growing in the region and is expected to continue to do so in the coming years.
Customer preferences: Patients suffering from respiratory diseases in Central & Western Europe prefer bronchodilator drugs due to their quick action and effectiveness in relieving symptoms such as shortness of breath and wheezing. The convenience of inhalers over traditional oral medications is also a major factor in the preference for bronchodilator drugs.
Trends in the market: Germany is the largest market for bronchodilator drugs in Central & Western Europe, followed by France and the United Kingdom. The market is dominated by a few major players, but there has been an increase in the number of generic drugs available, leading to more competition and lower prices. The trend towards personalized medicine is also affecting the market, with the development of drugs targeted at specific patient populations.
Local special circumstances: In France, the government has implemented measures to control the cost of healthcare, which has led to a decrease in the price of bronchodilator drugs. In the United Kingdom, the National Health Service (NHS) has been promoting the use of inhalers over traditional oral medications, leading to an increase in the use of bronchodilator drugs.
Underlying macroeconomic factors: The aging population in Central & Western Europe is a major driver of the bronchodilator drugs market, as respiratory diseases are more prevalent in older individuals. The high levels of air pollution in urban areas also contribute to the prevalence of respiratory diseases. The increasing prevalence of smoking in some countries is also a factor in the growth of the market. The overall growth of the healthcare sector in the region is also a driver of the market, as more individuals have access to healthcare and are being diagnosed with respiratory diseases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
